Appetite dysregulation and obesity in Western Communities

Research output: Contribution to conferenceAbstract

Abstract


The susceptibility of humans to obesity is far higher compared with other species and in man favours the deposition of fat. Amongst mammals humans have reported to have the highest levels of fatness than any other species with alteration in genes, high calorie diets and environmental factors that predispose humans to obesity. Environmental factors such stress, anxiety and depression are important to consider with the global increase in obesity and is possibly linked to the rise in individuals with mental disorders such as depression. The billion dollar drug industry that targets appetite control in obesity will address issues of post-prandial lipid metabolism and anti-obese drugs that control appetite and will improve post-prandial lipid metabolism that is closely connected to hypercholesterolemia and cardiovascular disease. Various factors effect appetite and brain metabolic diseases and require early intervention with drug therapy to prevent diseases of various organs such as non alcoholic fatty liver disease (NAFLD) in obesity related organ dysfunction. Postprandial lipid metabolism is abnormal in obese individuals and closely connected to the NAFLD and the metabolic syndrome in these individuals. Novel anti-obese designer drugs are involved in regulation of food intake and appetite control linked to cholesterol metabolism and lifespan. Anti-obese drugs regulate genes linked to appetite control and human fatness and are under evaluation in Western countries for the treatment of obesity and diabetes.
Original languageEnglish
Publication statusPublished - 26 Nov 2015
EventBit's 3rd Annual Global Health Conference-2015 - Kaohsiung, Taiwan, Province of China
Duration: 26 Nov 201528 Nov 2015

Conference

ConferenceBit's 3rd Annual Global Health Conference-2015
CountryTaiwan, Province of China
CityKaohsiung
Period26/11/1528/11/15

Fingerprint

Appetite
Obesity
Lipid Metabolism
Meals
Metabolic Brain Diseases
Designer Drugs
Depression
Appetite Regulation
Drug and Narcotic Control
Drug Industry
Hypercholesterolemia
Mental Disorders
Genes
Mammals
Cardiovascular Diseases
Anxiety
Fats
Cholesterol
Diet
Drug Therapy

Cite this

Martins, I. (2015). Appetite dysregulation and obesity in Western Communities. Abstract from Bit's 3rd Annual Global Health Conference-2015, Kaohsiung, Taiwan, Province of China.
Martins, Ian. / Appetite dysregulation and obesity in Western Communities. Abstract from Bit's 3rd Annual Global Health Conference-2015, Kaohsiung, Taiwan, Province of China.
@conference{1689860b49064ca8970cc697abbe0357,
title = "Appetite dysregulation and obesity in Western Communities",
abstract = "The susceptibility of humans to obesity is far higher compared with other species and in man favours the deposition of fat. Amongst mammals humans have reported to have the highest levels of fatness than any other species with alteration in genes, high calorie diets and environmental factors that predispose humans to obesity. Environmental factors such stress, anxiety and depression are important to consider with the global increase in obesity and is possibly linked to the rise in individuals with mental disorders such as depression. The billion dollar drug industry that targets appetite control in obesity will address issues of post-prandial lipid metabolism and anti-obese drugs that control appetite and will improve post-prandial lipid metabolism that is closely connected to hypercholesterolemia and cardiovascular disease. Various factors effect appetite and brain metabolic diseases and require early intervention with drug therapy to prevent diseases of various organs such as non alcoholic fatty liver disease (NAFLD) in obesity related organ dysfunction. Postprandial lipid metabolism is abnormal in obese individuals and closely connected to the NAFLD and the metabolic syndrome in these individuals. Novel anti-obese designer drugs are involved in regulation of food intake and appetite control linked to cholesterol metabolism and lifespan. Anti-obese drugs regulate genes linked to appetite control and human fatness and are under evaluation in Western countries for the treatment of obesity and diabetes.",
author = "Ian Martins",
year = "2015",
month = "11",
day = "26",
language = "English",
note = "Bit's 3rd Annual Global Health Conference-2015 ; Conference date: 26-11-2015 Through 28-11-2015",

}

Martins, I 2015, 'Appetite dysregulation and obesity in Western Communities' Bit's 3rd Annual Global Health Conference-2015, Kaohsiung, Taiwan, Province of China, 26/11/15 - 28/11/15, .

Appetite dysregulation and obesity in Western Communities. / Martins, Ian.

2015. Abstract from Bit's 3rd Annual Global Health Conference-2015, Kaohsiung, Taiwan, Province of China.

Research output: Contribution to conferenceAbstract

TY - CONF

T1 - Appetite dysregulation and obesity in Western Communities

AU - Martins, Ian

PY - 2015/11/26

Y1 - 2015/11/26

N2 - The susceptibility of humans to obesity is far higher compared with other species and in man favours the deposition of fat. Amongst mammals humans have reported to have the highest levels of fatness than any other species with alteration in genes, high calorie diets and environmental factors that predispose humans to obesity. Environmental factors such stress, anxiety and depression are important to consider with the global increase in obesity and is possibly linked to the rise in individuals with mental disorders such as depression. The billion dollar drug industry that targets appetite control in obesity will address issues of post-prandial lipid metabolism and anti-obese drugs that control appetite and will improve post-prandial lipid metabolism that is closely connected to hypercholesterolemia and cardiovascular disease. Various factors effect appetite and brain metabolic diseases and require early intervention with drug therapy to prevent diseases of various organs such as non alcoholic fatty liver disease (NAFLD) in obesity related organ dysfunction. Postprandial lipid metabolism is abnormal in obese individuals and closely connected to the NAFLD and the metabolic syndrome in these individuals. Novel anti-obese designer drugs are involved in regulation of food intake and appetite control linked to cholesterol metabolism and lifespan. Anti-obese drugs regulate genes linked to appetite control and human fatness and are under evaluation in Western countries for the treatment of obesity and diabetes.

AB - The susceptibility of humans to obesity is far higher compared with other species and in man favours the deposition of fat. Amongst mammals humans have reported to have the highest levels of fatness than any other species with alteration in genes, high calorie diets and environmental factors that predispose humans to obesity. Environmental factors such stress, anxiety and depression are important to consider with the global increase in obesity and is possibly linked to the rise in individuals with mental disorders such as depression. The billion dollar drug industry that targets appetite control in obesity will address issues of post-prandial lipid metabolism and anti-obese drugs that control appetite and will improve post-prandial lipid metabolism that is closely connected to hypercholesterolemia and cardiovascular disease. Various factors effect appetite and brain metabolic diseases and require early intervention with drug therapy to prevent diseases of various organs such as non alcoholic fatty liver disease (NAFLD) in obesity related organ dysfunction. Postprandial lipid metabolism is abnormal in obese individuals and closely connected to the NAFLD and the metabolic syndrome in these individuals. Novel anti-obese designer drugs are involved in regulation of food intake and appetite control linked to cholesterol metabolism and lifespan. Anti-obese drugs regulate genes linked to appetite control and human fatness and are under evaluation in Western countries for the treatment of obesity and diabetes.

M3 - Abstract

ER -

Martins I. Appetite dysregulation and obesity in Western Communities. 2015. Abstract from Bit's 3rd Annual Global Health Conference-2015, Kaohsiung, Taiwan, Province of China.